Skip to main content

Table 1 Baseline characteristics of study participants

From: Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine

Characteristic

AS+DP

N = 79

AS+AL

N = 71

QN + DP

N = 71

QN + AL

N = 79

Female (%)

36 (45.6)

36 (50.7)

24 (33.8)

37 (46.8)

Age in months*

17 (11–26)

16 (10–26)

17 (13–26)

18 (13–26)

Weight (kgs)*

9.5 (8–11.5)

9 (8.1–11)

9.8 (8.8–11)

9.2 (8.4–11)

Temperature (degrees Centigrade)*

38.8 (37.7–39.5)

39.1 (37.7–39.5)

39.1 (37.3–39.5)

38.6 (37.5–39.6)

Parasite density per uL, log10 copies*

4.82 (4.29–5.10)

4.79 (4.38–5.02)

4.72 (4.19–5.00)

4.73 (4.17–5.03)

Complications at admission, n (%)

 Hemoglobin (mg/dL)*

9.1 (7.9–10.5)

9.2 (8.4–10.6)

9.3 (8.4–10.4)

9.4 (8.0–10.3)

 Total white blood cell count (*103/uL)*

9.6 (6.9–13.2)

9.2 (7.5–12.3)

9.4 (7.7–12.1)

10.0 (7.0–14.3)

 Random blood sugar (mmol/L)*

7.3 (6.3–8.3)

6.8 (6.4–8.3)

6.8 (5.7–8.3)

7.4 (6.25–8.25)

 History of repeated convulsions n (%)

6 (7.6%)

3 (4.2%)

8 (11.3%)

1 (1.3%)

 History of inability to feed

26 (33.0%)

24 (34.0%)

22 (31.0%)

29 (36.7%)

 Prostration (extreme weakness)

22 (27.9%)

15 (21.13%)

21 (29.58%)

21 (26.58%)

 Hemoglobinuria

0

0

2 (2.8%)

0

 Jaundice

2 (2.5%)

0

3 (4.2%)

3 (3.8%)

 Severe anemia

0

0

1 (3%)

2 (2.5%)

 Respiratory distress

2 (2.5%)

6 (8.5%)

3 (4.2%)

5 (6.3%)

 Impaired consciousness

0

0

1 (1.4%)

0

 Abnormal bleeding

2 (2.5%)

1 (1.4%)

0

1 (1.3%)

 Hypoglycemia

0

0

0

1 (1.3%)